Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review

• Main Authors: Masaki Kobayashi, Kenjiro Sawada, Tadashi Kimura
• Format: Article
• Language: English
• Published: MDPI AG 2017-07-01
• Series: Cancers
• Subjects: integrin; ovarian cancer; angiogenesis; RGD peptide; volociximab
• Online Access: https://www.mdpi.com/2072-6694/9/7/83

Epithelial ovarian cancer is a fatal disease, with a cure rate of only 30%. Several recent studies have targeted integrins for cancer treatment. Preclinical studies have shown the effectiveness of several integrin inhibitors for blocking cancer progression, especially by blocking angiogenesis. Because the initial critical step in ovarian cancer metastasis is the attachment of cancer cells to the peritoneum or omentum and because clinical trials have provided positive results for anti-angiogenic therapy, therapies targeting integrins may be the most feasible approach for treating cancer. This review summarizes the current understanding of integrin biology in ovarian cancer metastasis and various therapeutic approaches involving integrin inhibitors. However, no integrin inhibitor has shown favorable results thus far. However, conjugates of cytotoxic agents with the triplet sequence arginine-glycine-aspartate (RGD) peptides targeting α5β1-, αvβ3-, and αvβ6-integrins may be promising integrin-targeting therapies for further clinical investigation.